Associations of disease duration and anti-citrullinated peptide antibody status with the effectiveness of abatacept in biologic-naïve patients with rheumatoid arthritis: Post hoc analysis of a multicentre, real-world observational study in Japan (ORIGAMI)

• Published in: Modern rheumatology Vol. 34; no. 2; pp. 297 - 306
• Main Authors: Misaki, Kenta, Tamura, Naoto, Azuma, Takanori, Shinoda, Koichiro, Tanaka, Masao, Fujiwara, Hiroshi, Tsuboi, Hideki, Kasama, Tsuyoshi, Yoshimi, Ryusuke, Hanyu, Tadamasa, Kusaka, Yoshiaki, Hirao, Makoto, Onishi, Makoto, Uchino, Ayumi, Izumiyama, Tomomasa, Yang, Kwang-Seok, Ogawa, Noriyoshi, Matsui, Kiyoshi, Kurasawa, Kazuhiro, Kawaai, Satoshi, Yasuoka, Hidekata, Okumura, Noriaki, Ueda, Yo, Tanaka, Eiichi, Inoue, Eisuke, Tsuritani, Katsuki, Matsumoto, Shigeru, Yamanaka, Hisashi, Harigai, Masayoshi
• Format: Journal Article
• Language: English
• Published: England 26.02.2024
• Subjects: Abatacept - therapeutic use; Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - diagnosis; Biological Products - therapeutic use; Humans; Japan; Treatment Outcome; Japan; disease activity; Abatacept; disease duration; anti-citrullinated peptide antibody; predictive factors
• ISSN: 1439-7595; 1439-7609
• DOI: 10.1093/mr/road045

The aim of the article is to investigate the associations of disease duration and anti-cyclic citrullinated peptide antibody (ACPA) status with the effectiveness of abatacept in biologic-naïve patients with rheumatoid arthritis (RA). We performed post hoc analyses of the Orencia® Registry in Geographically Assembled Multicenter Investigation (ORIGAMI) study of biologic-naïve RA patients aged ≥20 years with moderate disease activity who were prescribed abatacept. Changes in the Simplified Disease Activity Index (SDAI) and Japanese Health Assessment Questionnaire (J-HAQ) at 4, 24, and 52 weeks of treatment were analysed in patients divided according to ACPA serostatus (positive/negative), disease duration (<1/≥1 year), or both. SDAI scores decreased from baseline in all groups. SDAI scores tended to decrease more in the ACPA-positive group and disease duration <1-year group than in the ACPA-negative group and disease duration ≥1-year group, respectively. In the disease duration <1-year group, SDAI tended to decrease more in the ACPA-positive group than in the ACPA-negative group. Disease duration was independently associated with the change in SDAI and SDAI remission at Week 52 in multivariable regression models. These results suggest that starting abatacept within 1 year of diagnosis was associated with greater effectiveness of abatacept in biologic-naïve patients with RA and moderate disease activity.